trending Market Intelligence /marketintelligence/en/news-insights/trending/lsMwwnDwtWFYDk1SVh0k3g2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Biogen board authorizes $5B share buyback program


Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection


Banking Essentials Newsletter - February Edition


Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Biogen board authorizes $5B share buyback program

Biogen Inc. said its board of directors authorized a program to buy back up to $5 billion of its common stock.

The share repurchase program does not have an expiration date. All share repurchases under the program will be retired.

The current program is in addition to the buyback program authorized by the Cambridge, Mass.-based drugmaker's board in March.

Biogen develops and manufactures therapies for neurological and neurodegenerative diseases.